| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Conjugate | |
| Formulation | |
| Host | |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Purity | |
| Reactivity | |
| Shipping | |
| Species | |
| Storage | |
| Target |
Immunotherapy, CAR-T
Product Overview
Anti-PSMA-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of PSMA-CHO cells (BPS Bioscience #79641-H). PSMA (Prostate-Specific Membrane antigen), also known as FLOH1 (folate hydrolase 1) and NAALADase I (N-acetyl-L-aspartyl-L-glutamate peptidase I) is a transmembrane protein highly expressed in the intestine, the prostate, and the nervous system. The protein is a glutamate carboxypeptidase involved in folate metabolism and may be involved in pathological conditions such as hyperhomocysteinemia (intestine) and glutamate toxicity (nervous system). PSMA is overexpressed in prostate cancer cells and is the target of an increasing number of diagnostic and therapeutic approaches used for the treatment of prostate cancer.
| Clonality | Monoclonal (Bispecific) |
|---|---|
| Host | Human |
| Antibody Type | IgG1 |
| Isotype | IgG1 |
| Reactivity | Human |
| Purification | Protein A affinity purification (HEK293) |
| Purity | ≥90% |
| Molecular Weight | ~150 kDa (Heavy Chain: 50 kDa; Light Chain: 24 kDa) |
| Constructs | Anti-PSMA-Heavy and Light Chains, Anti CD3-Heavy and Light Chains |
| Formulation | 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol |
| Storage | At least 12 months at -80°C. |
Validated Applications
- Co-culture
- Reporter Assay
Assay conditions: See datasheet for detailed information
Immunogen / Antigen Information
Immunogen information not provided. Please refer to the product datasheet for detailed antigen information.
Cross-Reactivity & Specificity
Cross-reactivity data: Species reactivity as listed. No additional cross-reactivity data is available from the manufacturer.
Safety & Handling
Avoid freeze/thaw cycles.
For Research Use Only (RUO). Not for diagnostic, therapeutic, or clinical use. Handle with standard laboratory precautions (gloves, safety glasses, lab coat). Avoid freeze-thaw cycles. Consult SDS prior to use.
Related Products
- 60621
- 79641
- 100860
- 101076
This antibody has been validated for: Co-culture, Reporter Assay. Optimal dilutions and concentrations should be empirically determined for each specific application and sample type. Refer to the product datasheet for suggested starting conditions.
This antibody should be stored at the indicated temperature to maintain stability. Store at At least 12 months at -80°C.. Avoid repeated freeze-thaw cycles, which can reduce antibody performance and increase aggregation. Centrifuge briefly after thawing and keep on ice during use.
Please refer to the BPS Bioscience datasheet for detailed immunogen information.
Cross-reactivity data is limited; refer to the product datasheet for available information.
BPS Bioscience offers multiple antibody formats for key checkpoint and immunotherapy targets. Contact BioHippo (support@biohippo.com) or click "Talk to a Scientist" to inquire about additional conjugate formats, bulk quantities, or custom formulations.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
